(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged ADC, antibody-drug conjugate, ATM, ATR, Cancer, CEACAM5-targeting ADC, Claudin-18.2, Danny Bar-Zohar, DDR cascade, DNA-PK, Frank Jiang, Hengrui, HRS-1167, inhibitor, Jiangsu Hengrui Pharmaceuticals Co. Ltd., M9140, Merck, metastatic colorectal cancer, oncology, PARP, PARP1, poly (ADP-ribose) polymerase 1, SHR-A1904
(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abiraterone, AstraZeneca, Cancer, chemotherapy, Eastern Cooperative Oncology Group, EcoG, hormones, HRR, IDMC, Independent Data Monitoring Committee, Lynparza, mCRPC, MSD, MSD Research Laboratories, Olaparib, PARP, PROpel Phase III, prostate cancer, Roy Baynes, rPFS, Susan Galbraith
Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Dave Fredrickson, inhibitor, Japan, Lynparza, Lynparza (olaparib), ovarian cancer, PARP, Roy Baynes
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?